Table 1.
Demographics of Pregnant WLHIV on Elvitegravir by Medication Group
| All (n = 134) |
EVG Initiated Before Pregnancy & Continued Through Delivery (Group 1) (n = 68) | EVG Initiated During Pregnancy (Group 2) (n = 52) | EVG Discontinued During Pregnancy (Group 3) (n = 14) | P Value | 1 vs 2 | 1 vs 3 | 2 vs 3 | No. | |
|---|---|---|---|---|---|---|---|---|---|
| Age at delivery, y | 28.0 (24.0–33.0) | 28.0 (25.0–33.5) | 28.0 (23.8–32.2) | 25.0 (21.2–31.5) | .239 | 0.222 | 0.136 | 0.556 | 133 |
| Race | .023 | 0.014 | 0.589 | 0.020 | 133 | ||||
| Asian | 1 (0.75) | 1 (1.47) | 0 (0.00) | 0 (0.00) | |||||
| Black or African American | 110 (82.7) | 52 (76.5) | 48 (94.1) | 10 (71.4) | |||||
| Hispanic or Latino | 6 (4.51) | 4 (5.88) | 0 (0.00) | 2 (14.3) | |||||
| Native Hawaiian/ Pacific Islander | 1 (0.75) | 0 (0.00) | 1 (1.96) | 0 (0.00) | |||||
| White | 15 (11.3) | 11 (16.2) | 2 (3.92) | 2 (14.3) | |||||
| BMI at first prenatal visit, kg/m2 | 29.6 (23.2–35.8) | 31.5 (22.8–36.9) | 28.1 (23.7–34.6) | 27.5 (22.9–32.6) | .668 | 0.463 | 0.488 | 0.811 | 132 |
| Parity | .024 | 0.034 | 0.057 | 0.753 | 134 | ||||
| Nulliparous | 30 (22.4) | 9 (13.2) | 16 (30.8) | 5 (35.7) | |||||
| Multiparous | 104 (77.6) | 59 (86.8) | 36 (69.2) | 9 (64.3) | |||||
| Tobacco use | .758 | 0.640 | 0.748 | 0.638 | 132 | ||||
| Current | 26 (19.7) | 11 (16.7) | 12 (23.1) | 3 (21.4) | |||||
| Never | 83 (62.9) | 43 (65.2) | 30 (57.7) | 10 (71.4) | |||||
| Past | 23 (17.4) | 12 (18.2) | 10 (19.2) | 1 (7.14) | |||||
| History of PTB | 19 (14.2) | 11 (16.2) | 6 (11.5) | 2 (14.3) | .771 | 0.647 | 1.000 | 0.674 | 134 |
| Comorbidities–hypertension | 25 (18.7) | 13 (19.1) | 9 (17.3) | 3 (21.4) | .949 | 0.987 | 1.000 | 0.708 | 134 |
| Comorbidities–diabetes | 1 (0.75) | 1 (1.47) | 0 (0.00) | 0 (0.00) | 1.000 | 1.000 | 1.000 | . | 134 |
| Comorbidities–active substance Abuse | 25 (18.7) | 11 (16.2) | 12 (23.1) | 2 (14.3) | .654 | 0.473 | 1.000 | 0.716 | 134 |
| Comorbidities–psychiatric illness | 55 (41.0) | 32 (47.1) | 18 (34.6) | 5 (35.7) | .355 | 0.237 | 0.630 | 1.000 | 134 |
| Start EVG >2nd trimester | 8 (5.97) | 0 (0.00) | 8 (15.4) | 0 (0.00) | .001 | 0.001 | 0.187 | 134 | |
| Age at HIV diagnosis, y | 22.0 (18.0–27.0) | 22.0 (18.0–26.0) | 23.0 (17.8–30.0) | 19.0 (19.0–23.0) | .407 | 0.542 | 0.270 | 0.223 | 133 |
| Congenital infection | 19 (14.3) | 8 (11.8) | 9 (17.3) | 2 (15.4) | .662 | 0.549 | 0.659 | 1.000 | 133 |
| HIV diagnosis | <.001 | <0.001 | 0.037 | 0.198 | 131 | ||||
| Current pregnancy | 23 (17.6) | 0 (0.00) | 21 (40.4) | 2 (15.4) | |||||
| Prior pregnancy | 28 (21.4) | 18 (27.3) | 7 (13.5) | 3 (23.1) | |||||
| Not related to pregnancy | 80 (61.1) | 48 (72.7) | 24 (46.2) | 8 (61.5) |
Data are presented as No. (%) or median (interquartile range). Virologic suppression: HIV-1 RNA <40 copies.
Abbreviations: BMI, body mass index; EVG, elvitegravir; PTB, preterm birth; WLHIV, women living with HIV.